Sponsored Links
| Advaxis Phase I Survival Update |
 |
 |
 |
| Medical News - Cervical Cancer HPV | |||
|
Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy... Read more: Cervical Cancer / HPV Vaccine News From Medical News Today
|